Observational Post-Authorisation Safety Study of Asenapine (Sycrest)

Inclusion Criteria: * Patients for whom a study questionnaire containing useful information has been returned Exclusion Criteria: * Patients who do not provide consent * Patients within selected institutions (for example prisons) * Patients who commenced treatment between date of market launch (to be confirmed) and study start * Enrolled patients for whom both the baseline and 12-week questionnaires are returned blank (contain no clinical information) * Enrolled patients for whom the psychiatrist, designated member of clinical care team, or study facilitator from the DSRU reports that the patient did not take or was never prescribed asenapine * Enrolled patients for whom there is evidence to suggest duplication of patients * Enrolled patients for whom informed written or verbal notification is received by DSRU indicating that they no longer wish to participate at any stage of the study